Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.
Paolo Antonio AsciertoReinhard DummerHelen J GogasAna AranceMario MandalaGabriella LiszkayClaus GarbeDirk SchadendorfIvana KrajsovaRalf GutzmerVanna Chiarion SileniCaroline DutriauxJan Willem B de GrootNaoya YamazakiCarmen LoquaiCaroline RobertKeith T FlahertyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
COMBO300 improved PFS, ORR, and tolerability compared with ENCO300, confirming the contribution of binimetinib to efficacy and safety.